Informa’s drug development database Biomedtracker believes that more than 50 candidate medicines, across 15 broad therapeutic categories and involving more than 60 companies, may reach the US market over the next 12 to 18 months, according to its new report.
The products include MacroGenic’s margetuximab, Genfit’s elafibranor, Allergan’s ubrogepant, Merck & Co’s ebola vaccine and GlaxoSmithKline’s antibody-drug conjugate GSK2857916.







